Cited by 64Alzheimer's disease research and treatmentsStress Responses and CortisolNeuroscience and Neuropharmacology Research

Stress-induced anhedonia is associated with an increase in Alzheimer’s disease-related markers

Open access
Briones, A, Gagno, S, Martisova, E, Dobarro, M, Aisa, B, Solas, M, Tordera, R, Ramírez, MJ·2012·British Journal of Pharmacology

Abstract

BACKGROUND AND PURPOSE: Stress is believed to be associated with the development of neuropsychiatric disorders, including Alzheimer's disease (AD). We have studied mechanisms implicated in vulnerability to stress and the relationship with changes in AD-related markers. EXPERIMENTAL APPROACH: Anhedonia induced by a chronic mild stress (CMS) procedure, applied for 6 weeks, was used to select rats vulnerable or resistant to stress. Sucrose intake, the Porsolt forced swimming test and cognitive deficits in the novel object recognition test (NORT) were used to characterize vulnerable and resilient rats. The antidepressant venlafaxine (20 mg·kg(-1) p.o.) or saline was administered daily during the last 2 weeks of CMS. Biochemical markers affected by stress, PKB, ERK and synaptophysin, and those associated with AD, amyloid β-protein (Aβ), β-secretase (BACE1) and τ phosphorylation, were measured in the hippocampus. KEY RESULTS: After CMS, 40% of rats were resistant to the development of anhedonia (CMS-resistant to stress), whereas the remaining were responsive [CMS-anhedonic (CMSA)]. Only CMSA rats displayed significant increases in immobility time in the forced swimming test and cognitive deficits in the NORT, and significant decreases in synaptophysin, phosphorylated PKB and phosphorylated ERK1/2 expression in the hippocampus. Increased levels of Aβ40, BACE1 and τ phosphorylation were also found only in CMSA rats. All these effects in CMSA rats were reverted by treatment with venlafaxine. CONCLUSIONS AND IMPLICATIONS: Vulnerability to stress might constitute a risk factor for the development of AD, and pharmacological treatment with venlafaxine may represent a therapeutic strategy for the treatment of stress-related disorders, including AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1476-5381.2011.01602.x

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Briones, A., Gagno, S., Martisova, E., Dobarro, M., Aisa, B., Solas, M., Tordera, R., & Ramírez, M.
Affiliations
  • Universidad Autónoma de Chiapas (MX)
  • Universidad de Navarra (ES)
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2012-01-25
Volume
165
Issue
4
Pages
897-907
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W1870249730
Cited by
64
References
62
Citations by year
2026: 1 · 2025: 3 · 2023: 7 · 2022: 2 · 2021: 5 · 2020: 2 · 2019: 4 · 2018: 7 · 2017: 4 · 2016: 6 · 2015: 9 · 2014: 8 · 2013: 3 · 2012: 2
FWCI
3.05
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
Consejo Nacional de Ciencia y Tecnología
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Behavioral Neuroscience › Stress Responses and Cortisol
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
Keywords
chronic mild stress, Alzheimer's disease, stress vulnerability, venlafaxine, amyloid-beta, BACE1, tau phosphorylation, synaptophysin, Akt, ERK1/2, hippocampus, cognitive impairment, antidepressant treatment
MeSH terms
Venlafaxine Hydrochloride, Alzheimer Disease, Animals, Cognition, Corticosterone, Cyclohexanols, Hippocampus, Male, Self Administration, Stress, Psychological, Sucrose, Biomarkers, Amyloid beta-Peptides, Aspartic Acid Endopeptidases, Synaptophysin, tau Proteins, Rats, Wistar, Antidepressive Agents, Second-Generation, MAP Kinase Signaling System, Vesicular Transport Proteins, Proto-Oncogene Proteins c-akt, Rats, Amyloid Precursor Protein Secretases, Anhedonia

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review